Overview

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the 2-year progression-free survival rate.
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Bortezomib
Melphalan
Prednisone